Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Atlas of clinical PET-CT in treatment response evaluation in oncology / / Stefano Fanti, Gopinath Gnanasegaran, Ignasi Carrió, editors
| Atlas of clinical PET-CT in treatment response evaluation in oncology / / Stefano Fanti, Gopinath Gnanasegaran, Ignasi Carrió, editors |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (483 pages) |
| Disciplina | 616.99407575 |
| Soggetto topico |
Cancer - Tomography
Quimioteràpia del càncer Radioteràpia Tomografia per emissió de positrons |
| Soggetto genere / forma |
Llibres electrònics
Atles (Científic) |
| ISBN | 3-030-68858-5 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Contents -- List of Contributors -- Part I: Therapy Response Evaluation: Science and Practice -- 1: Treatment Response Evaluation: Science and Practice -- 1.1 Introduction -- 1.2 Criteria for Evaluating Response -- 1.3 Traditional Response Criteria -- 1.4 Incorporation of Molecular Imaging into Response Criteria -- 1.5 Response Criteria and Immunotherapy -- 1.6 Practical Considerations -- References -- 2: CT in Treatment Response Assessment in Oncology -- 2.1 Introduction -- 2.2 Current Response Assessment Criteria for Chemotherapy and Targeted Therapies -- 2.3 Pitfalls of RECIST 1.1 -- 2.4 mRECIST in HCC -- 2.5 Lugano Classification in Lymphoma -- 2.6 Response Assessment Criteria in Immunotherapy -- 2.7 Conclusion -- References -- 3: MRI and Diffusion-Weighted MRI in Treatment Response Evaluation Overview -- 3.1 Introduction -- 3.2 Response Evaluation by Tumour Burden or Anatomical Parameters -- 3.2.1 WHO and RECIST Criteria -- 3.2.2 iRECIST -- 3.2.3 Other Response Evaluation by Anatomical MRI in Specific Disease Contexts -- 3.2.3.1 Brain Tumour -- 3.2.3.2 Hepatocellular Carcinoma (HCC) -- 3.2.3.3 Rectal Cancer -- 3.3 Response Evaluation with Diffusion-Weighted Imaging (DWI) -- 3.4 Conclusion -- References -- 4: PET and PET-CT in Treatment Response Evaluation: Overview -- 4.1 Introduction: Why Is Tumor Response Assessed by Imaging? -- 4.2 Assessment of Tumor Response: When and How? -- 4.2.1 Response Assessment by FDG PET -- 4.2.1.1 Response Assessment in Lymphoma -- 4.2.2 Response Assessment with Other PET Imaging Agents -- 4.2.3 Timing of Response Assessment -- 4.3 Responders vs. Nonresponders -- 4.4 Management and Type of Treatment -- 4.5 Common Patterns, Pitfalls, Variants, Advantages, and Limitations -- 4.5.1 Standardized Imaging Protocol -- 4.5.2 Impact of Therapy on FDG Metabolism.
4.5.3 Radiation Therapy -- 4.5.4 Immunotherapy -- 4.5.5 Clinical Image Interpretation -- References -- 5: Conventional Radiological Techniques and PET-CT in Treatment Response Evaluation in Postsurgical Setting -- 5.1 Introduction -- 5.2 Computed Tomography (CT) -- 5.3 Magnetic Resonance Imaging (MRI) -- 5.4 Positron Emission Tomography (PET) -- 5.5 Other Radiotracers (Neuroendocrine Tumors, Prostate Cancer) -- 5.6 Conclusion -- References -- 6: Conventional Radiological and PET-CT Assessment of Treatment Response Evaluation in Chemotherapy Setting -- 6.1 Introduction -- 6.2 Conventional Radiological Techniques -- 6.3 PET/CT in Response Assessment to Chemotherapy -- 6.3.1 EORTC -- 6.3.2 IHP Criteria for Lymphoma -- 6.3.3 Deauville Criteria for Lymphoma -- 6.3.4 PERCIST -- 6.4 MRI and CT in Response Assessment to Chemotherapy -- 6.5 Evaluation of Response to Chemotherapy in Individual Tumours -- 6.5.1 Oesophageal and Gastric Cancer -- 6.5.2 Colorectal Cancer -- 6.5.3 Hepatocellular Carcinoma -- 6.5.4 Pancreatic Cancer -- 6.5.5 Lung Cancer -- 6.5.6 Lymphoma -- 6.5.7 Head and Neck Cancer -- 6.5.8 Breast Cancer -- 6.5.9 Other Tumours -- 6.6 Conclusion -- References -- 7: Conventional Radiological Techniques and PET-CT in Treatment Response Evaluation in Post-Radiotherapy Setting -- 7.1 Introduction -- 7.2 Functional Imaging for Disease Response Assessment to Radiotherapy -- 7.2.1 Functional, Metabolic PET Imaging -- 7.2.1.1 Glucose Metabolism -- 7.2.1.2 Tumor Hypoxia -- 7.2.1.3 Tumor Cell Proliferation -- 7.2.1.4 Apoptosis -- 7.2.1.5 Amino Acid Transport and Protein Synthesis -- 7.2.1.6 Cell Membrane Synthesis -- 7.2.1.7 Epidermal Growth Factor Receptor Status -- 7.2.2 Functional MR Imaging Techniques -- 7.2.2.1 Dynamic Contrast-Enhanced MR Imaging -- 7.2.2.2 Diffusion-Weighted MR Imaging -- 7.2.2.3 BOLD Imaging. 7.2.2.4 MR Spectroscopy -- 7.2.3 Functional Imaging with Perfusion CT -- 7.2.4 Emerging Integrated Hybrid Imaging Techniques -- 7.2.4.1 Integrated PET/CT Perfusion Imaging -- 7.2.4.2 Integrated PET-MR Imaging -- 7.3 Assessment of Treatment Response After Radiotherapy -- 7.3.1 Anatomic Response Criteria (WHO, RECIST) -- 7.3.1.1 WHO Criteria -- 7.3.1.2 RECIST v1.1 -- 7.3.1.3 Limitations of Anatomic Response Criteria -- 7.3.2 Metabolic Response Criteria -- 7.3.2.1 Qualitative Assessment -- 7.3.2.2 Quantitative Assessment (PERCIST v1.0) -- 7.4 Current Uses of FDG PET/CT in Treatment Response Following Radiation Therapy -- 7.4.1 Head and Neck Cancer -- 7.4.2 Esophageal Carcinoma -- 7.4.3 Rectal Carcinoma -- 7.4.4 Brain Tumors -- 7.4.5 Cervical Carcinoma -- 7.4.6 Lung Carcinoma -- 7.4.7 Hepato-Pancreatico-Biliary Tumors, Particularly Pancreatic Carcinoma and Liver Metastases (Postselective Internal Radiotherapy Treatment) -- References -- 8: Conventional Radiological Techniques and PET-CT in Treatment Response Evaluation in Immunotherapy Settings -- 8.1 Introduction -- 8.2 Management: Type of Treatments/Regimes -- 8.2.1 Melanoma -- 8.2.2 NSCLC -- 8.2.3 Other Solid Tumors -- 8.3 Pathophysiology -- 8.4 Assessment of Treatment Response -- 8.4.1 Anatomic Response Assessment -- 8.4.2 Metabolic Response Criteria -- 8.4.3 Responders Vs. Non-Responders -- 8.4.4 Pitfalls and beyond (Pseudo-, Hyper-Progression, irAEs, Brain Mets, Cost-Effectiveness) -- References -- 9: Treatment Response Evaluation of Bone Metastases Using 18F-NaF -- 9.1 Introduction -- 9.2 Management and Types of Treatments -- 9.2.1 Baseline 18F-Fluoride PET/CT -- 9.2.1.1 Prostate Cancer -- 9.2.1.2 Breast Cancer -- 9.2.1.3 Lung Cancer -- 9.2.1.4 Thyroid Cancer -- 9.2.1.5 Renal Cell Cancer. 9.3 Assessment of Treatment Response (Postsurgical, Post Chemotherapy, Post Radiotherapy, Neoadjuvant, and Immunotherapy Settings) -- 9.3.1 Interim 18F-Fluoride PET/CT -- 9.3.1.1 Prostate Cancer -- 9.3.1.2 Breast Cancer -- 9.3.2 Follow-Up 18F-Fluoride PET/CT -- 9.3.2.1 Prostate Cancer -- 9.3.2.2 Breast Cancer -- 9.3.2.3 Multiple Myeloma -- 9.3.2.4 Metastatic Primary Bone Tumors -- 9.3.3 Conclusions -- 9.4 Common Patterns, Pitfalls, Variants, Advantages, and Limitations -- References -- 10: Reporting Post-Therapy Scans -- 10.1 Introduction -- 10.2 Patient Preparation -- 10.3 Clinical Details -- 10.4 Questions to Ask Patient -- 10.5 When to Scan -- 10.6 What to Look for in the Scans -- 10.7 How to Describe, Report Post-Therapy Finding Scores, Criteria, etc. (Post-Surgical, Post-Chemotherapy, Post-Radiotherapy, and Post-Immunotherapy Settings) -- 10.8 Common and Less Common Findings -- 10.9 How to Interpret the Findings: Dos and Don'ts -- 10.9.1 What to Do -- 10.9.2 What Not to Do -- 10.10 What to Advise the Referrers -- References -- Part II: Therapy Response Evaluation: Clinical Atlas -- 11: 18F-FDG PET/CT in Treatment Response Evaluation in Head and Neck Cancer -- 11.1 Case 1 -- 11.2 Case 2 -- 11.3 Case 3 -- 11.4 Case 4 -- 11.5 Case 5 -- 11.6 Case 6 -- 11.7 Case 7 -- 11.8 Case 8 -- 11.9 Case 9 -- 11.10 Case 10 -- 11.11 Case 11 -- 11.12 Case 12 -- 11.13 Case 13 -- 11.14 Case 14 -- 11.15 Case 15 -- Suggested Reading -- Case 3 -- 12: PET/CT in Treatment Response Evaluation: Lung Cancer -- 12.1 Introduction -- References -- 13: 18F-FDG PET/CT and Non 18F-FDG-PET/CT in Treatment Response Evaluation in Neuro-Oncology -- 13.1 Introduction -- 13.2 PET Tracers Used in Neuro-Oncology -- 13.3 Case 1 -- 13.4 Case 2 -- 13.5 Case 3 -- 13.6 Case 4 -- 13.7 Case 5 -- 13.8 Case 6 -- 13.9 Case 7 -- 13.10 Case 8. 13.11 Case 9 -- 13.12 Case 10 -- 13.13 Case 11 -- 13.14 Case 12 -- 13.15 Case 13 -- 13.16 Case 14 -- 13.17 Case 15 -- References -- 14: PET/CT in the Assessment of Treatment Response in Hepatobiliary, Gall Bladder and Pancreatic Malignancies -- 14.1 Introduction -- 14.2 Case 1 -- 14.3 Case 2 -- 14.4 Case 3 -- 14.5 Case 4 -- 14.6 Case 5 -- 14.7 Case 6 -- 14.8 Case 7 -- 14.9 Case 8 -- 14.10 Case 9 -- 14.11 Case 10 -- 14.12 Case 11 -- 14.13 Case 12 -- 14.14 Case 13 -- 14.15 Case 14 -- 14.16 Case 15 -- 14.17 Case 16 -- 14.18 Case 17 -- 14.19 Case 18 -- Suggested Reading -- Introduction -- Case 1 -- Case 2 -- Case 3 -- Case 4 -- Case 6 -- Case 7 -- Case 8 -- Case 11 -- 15: 18F-FDG PET/CT in Treatment Response Evaluation: Gastroesophageal Cancer -- 15.1 Introduction -- 15.2 Case No. 1: Radiation-Induced Esophagitis -- 15.3 Case No. 2: Radiation-Induced Pneumonitis -- 15.4 Case No. 3: Post Transthoracic Esophagectomy (TTE) Appearance -- 15.5 Case No. 4: Aspiration Pneumonia -- 15.6 Case No. 5: Recurrent Aspiration Pneumonia -- 15.7 Case No. 6: Tracheoesophageal Fistula (TOF) -- 15.8 Case No. 7: Upper Esophageal Mass with Complete Response Post CTRT -- 15.9 Case No. 8: Post CTRT Complete Response with Inflammatory Changes in the Esophagus -- 15.10 Case No. 9: Complete Response on PET/CT with Microscopic Residual Disease on Histopathology -- 15.11 Case No. 10: Posttreatment Changes Vs. Residual Disease -- 15.12 Case No. 11: Partial Response to Treatment -- 15.13 Case No. 12: Stable Disease with Radiation-Induced Esophagitis -- 15.14 Case No. 13: GE Junction Mass with Partial Response -- 15.15 Case No. 14: Complete Response -- 15.16 Case No. 15: Coexisting Malignancy and Granulomatous Infection -- 15.17 Case No. 16: Esophageal Primary with Coexisting Tuberculous Infection in the Lungs. 15.18 Case No. 17: GE Junction and Proximal Stomach Mass with Partial Response. |
| Record Nr. | UNINA-9910491028203321 |
| Cham, Switzerland : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Atlas of Response to Immunotherapy / / edited by Egesta Lopci, Stefano Fanti
| Atlas of Response to Immunotherapy / / edited by Egesta Lopci, Stefano Fanti |
| Edizione | [1st ed. 2020.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2020 |
| Descrizione fisica | 1 online resource (VIII, 127 p. 111 illus., 100 illus. in color.) |
| Disciplina |
616.07548
616.079 |
| Soggetto topico |
Nuclear medicine
Oncology Immunology Radiology Nuclear Medicine Oncology Diagnostic Radiology |
| ISBN | 3-030-31113-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | PART I BRIEF INTRODUCTION: Immunotherapy in oncology -- Evolution of response criteria -- Part II DIESEASE-ORIENTED APPLICATIONS: CNS -- Thorax -- Melanoma -- Gastrointestinal -- Genitourinary -- Hematologic -- Other tumor types -- PART III PITFALLS AND IMMUNE-RELATED ADVERSE EVENTS (IrAEs) PART IV IMMUNO-PET. |
| Record Nr. | UNINA-9910369940703321 |
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Molecular Imaging in Multiple Myeloma / / edited by Cristina Nanni, Stefano Fanti, Lucia Zanoni
| Molecular Imaging in Multiple Myeloma / / edited by Cristina Nanni, Stefano Fanti, Lucia Zanoni |
| Edizione | [1st ed. 2019.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2019 |
| Descrizione fisica | 1 online resource (138 pages) |
| Disciplina | 616.99418 |
| Soggetto topico |
Nuclear medicine
Hematology Oncology Nuclear Medicine Oncology |
| ISBN | 3-030-19019-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | 1.Multiple Myeloma: clinical aspects -- 2. What does a clinician need from new imaging procedures? -- 3.FDG PET in Multiple Myeloma -- 4. Role of Standard Magnetic Resonance Imaging -- 5.Whole Body Diffusion-Weighted Magnetic Resonance Imaging: A new era for whole body imaging in myeloma? -- 6.CXCR4 imaging in Multiple Myeloma -- 7.PET/CT with Standard NON-FDG Tracers -- 8. The issue of interpretation -- 9. Clinical Teachning Cases: FDG PET/CT . |
| Record Nr. | UNINA-9910349363203321 |
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2019 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Oncological PET/CT with Histological Confirmation / / edited by Juliano Cerci, Stefano Fanti, Dominique Delbeke
| Oncological PET/CT with Histological Confirmation / / edited by Juliano Cerci, Stefano Fanti, Dominique Delbeke |
| Edizione | [1st ed. 2016.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2016 |
| Descrizione fisica | 1 online resource (100 p.) |
| Disciplina | 610 |
| Soggetto topico |
Nuclear medicine
Oncology Pathology Nuclear Medicine Oncology |
| ISBN | 3-319-27880-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | PART I. Biopsy guided PET/CT: Principle of biopsy guided imaging.- FDG PET/CT to guide biopsy: methods.- FDG PET/CT to guide biopsy: type of acess.- PART II. FDG PET/CT in lymphoma: Need of biopsy in lymphoma.- FDG PET/CT to guide biopsy in lymphoma: results.- PART III. FDG PET/CT in pancreatic lesions:Need of biopsy in pancreatic lesions.- FDG PET/CT to guide biopsy in pancreatic lesions: results.- PART IV. FDG PEM in breast lessions: Need of biopsy in breast lesions.- FDG PEM to guide biopsy in breast lesions: results -- PART V. PET/CT and CNS malignancies: Need of biopsy in CNS malignancies -- FDG PET/CT to guide biopsy in CNS: results -- PART VI. PET/CT and prostate cancer -- Choline PET/CT to guide biopsy in prostate cancer diagnosis -- PART VII. FLT PET/CT in cancer diagnosis: FLT PET/CT in cancer diagnosis: results. |
| Record Nr. | UNINA-9910254509803321 |
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2016 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
PET/CT in Neuroendocrine Tumors / / edited by Valentina Ambrosini, Stefano Fanti
| PET/CT in Neuroendocrine Tumors / / edited by Valentina Ambrosini, Stefano Fanti |
| Edizione | [1st ed. 2016.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2016 |
| Descrizione fisica | 1 online resource (87 p.) |
| Disciplina | 616.99437 |
| Collana | PET/CT |
| Soggetto topico |
Nuclear medicine
Oncology Neurology Nuclear Medicine Oncology Neurology |
| ISBN | 3-319-29203-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Neuroendocrine Tumours: Epidemiology -- Pathology -- Management -- Radiological Imaging -- Radionuclide Imaging. PET/ CT in Neuroendocrine Tumors: Basic Principles of PET/ CT imaging -- Radiopharmaceuticals -- PET/ CT in Neuroendocrine Tumours. |
| Record Nr. | UNINA-9910254544703321 |
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2016 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Philosophy of advanced medical imaging / / Elisabetta Lalumera, Stefano Fanti, editors
| Philosophy of advanced medical imaging / / Elisabetta Lalumera, Stefano Fanti, editors |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (viii, 129 pages) : illustrations |
| Disciplina | 616.0754 |
| Collana | SpringerBriefs in Ethics |
| Soggetto topico | Diagnostic imaging |
| ISBN | 3-030-61412-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910447259803321 |
| Cham, Switzerland : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Radiology for PET/CT Reporting / / by Cristina Nanni, Stefano Fanti, Lucia Zanoni
| Radiology for PET/CT Reporting / / by Cristina Nanni, Stefano Fanti, Lucia Zanoni |
| Autore | Nanni Cristina |
| Edizione | [1st ed. 2014.] |
| Pubbl/distr/stampa | Berlin, Heidelberg : , : Springer Berlin Heidelberg : , : Imprint : Springer, , 2014 |
| Descrizione fisica | 1 online resource (154 p.) |
| Disciplina | 616.07572 |
| Soggetto topico |
Nuclear medicine
Radiology Nuclear Medicine Imaging / Radiology |
| ISBN | 3-642-40294-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Normal CT slice by slice: Brain -- Head and neck -- Thorax -- Abdomen -- Pelvis -- Para-physiological CT findings: Brain -- Head and neck -- Thorax -- Abdomen -- Pelvis -- Pathologic CT findings: Brain -- Head and neck -- Thorax -- Abdomen -- Pelvis -- MR for nuclear medicine: Brain -- Bone -- Pelvis. |
| Record Nr. | UNINA-9910300096703321 |
Nanni Cristina
|
||
| Berlin, Heidelberg : , : Springer Berlin Heidelberg : , : Imprint : Springer, , 2014 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Role of Medical Imaging in Cancers . Volume 1
| Role of Medical Imaging in Cancers . Volume 1 |
| Autore | Fanti Stefano |
| Pubbl/distr/stampa | Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2021 |
| Descrizione fisica | 1 electronic resource (312 pages) |
| Soggetto topico | Medicine |
| Soggetto non controllato |
positron emission tomography
head and neck neoplasms neovascularization pathologic PET/CT urothelial carcinoma bladder cancer upper tract urothelial carcinoma survival PET PSMA prostate DCFPyL DCFBC PSMA-1007 ovarian cancer relapse SUVmax targeted therapy prognosis soft tissue sarcoma (STS) pazopanib dynamic 18F-FDG PET/CT SUV two-tissue compartment model magnetic resonance imaging machine learning diffusion perfusion texture analysis squamous cell carcinoma of the head and neck diffusion-weighted imaging malignant pleural mesothelioma pleural dissemination empyema pleural effusion mCRPC SPECT/CT Computer-assisted diagnosis XOFIGO Therapy response assessment circulating miRNAs breast cancer imaging parameters PET/MRI biomarkers triple negative breast cancer VCAM-1 SPECT imaging sdAbs Hounsfield unit computed tomography adipose tissue precision oncology FDG-PET/CT PERCIST metastatic breast cancer prostate cancer 18F-FACBC recurrence meta-analysis review meningioma somatostatin receptor neuroimaging radionuclide therapy breast imaging marker radiomics Yin Yang 1 PDAC Mesothelin noninvasive imaging receptor status molecular imaging nuclear medicine guidelines overutilization epistemology consensus mantle cell lymphoma 18F-FDG PET/CT Deauville criteria Radium-223 FDG castrate resistant prostate cancer programmed cell death 1 receptor diagnostic imaging CTLA-4 Antigen Immunotherapy Adoptive radioactive tracers radionuclide imaging CD8-Positive T-Lymphocytes PI-RADS diffusion kurtosis imaging dynamic contrast-enhanced magnetic resonance imaging 68Gallium-PSMA PET/CT prostate-specific-antigen PSA kinetics thresholds biochemical recurrence optimal cutoff level non-small-cell lung cancer circulating tumor cells immunotherapy response to treatment head and neck cancer HPV EBV p16 Molecular imaging miRNA expression radiogenomics radiomic diagnosis biomarker glioblastoma radiation therapy MRI diffusion tensor imaging Hodgkin lymphoma diffuse large B-cell lymphoma staging response assessment locally advanced cervical cancer concurrent chemoradiotherapy treatment response follow up cystic tumor International Consensus Guidelines intraductal papillary mucinous neoplasms pancreatic neoplasms PD-1 PD-L1 response to therapy NSCLC positron-emission tomography single-photon emission computed tomography immune checkpoint inhibitors gold nanoparticle heat shock protein 70 spectral-CT |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910557432103321 |
|
Fanti Stefano
|
||
| Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2021 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Role of Medical Imaging in Cancers . Volume 2
| Role of Medical Imaging in Cancers . Volume 2 |
| Autore | Fanti Stefano |
| Pubbl/distr/stampa | Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2021 |
| Descrizione fisica | 1 electronic resource (228 p.) |
| Soggetto topico | Medicine |
| Soggetto non controllato |
positron emission tomography
head and neck neoplasms neovascularization pathologic PET/CT urothelial carcinoma bladder cancer upper tract urothelial carcinoma survival PET PSMA prostate DCFPyL DCFBC PSMA-1007 ovarian cancer relapse SUVmax targeted therapy prognosis soft tissue sarcoma (STS) pazopanib dynamic 18F-FDG PET/CT SUV two-tissue compartment model magnetic resonance imaging machine learning diffusion perfusion texture analysis squamous cell carcinoma of the head and neck diffusion-weighted imaging malignant pleural mesothelioma pleural dissemination empyema pleural effusion mCRPC SPECT/CT Computer-assisted diagnosis XOFIGO Therapy response assessment circulating miRNAs breast cancer imaging parameters PET/MRI biomarkers triple negative breast cancer VCAM-1 SPECT imaging sdAbs Hounsfield unit computed tomography adipose tissue precision oncology FDG-PET/CT PERCIST metastatic breast cancer prostate cancer 18F-FACBC recurrence meta-analysis review meningioma somatostatin receptor neuroimaging radionuclide therapy breast imaging marker radiomics Yin Yang 1 PDAC Mesothelin noninvasive imaging receptor status molecular imaging nuclear medicine guidelines overutilization epistemology consensus mantle cell lymphoma 18F-FDG PET/CT Deauville criteria Radium-223 FDG castrate resistant prostate cancer programmed cell death 1 receptor diagnostic imaging CTLA-4 Antigen Immunotherapy Adoptive radioactive tracers radionuclide imaging CD8-Positive T-Lymphocytes PI-RADS diffusion kurtosis imaging dynamic contrast-enhanced magnetic resonance imaging 68Gallium-PSMA PET/CT prostate-specific-antigen PSA kinetics thresholds biochemical recurrence optimal cutoff level non-small-cell lung cancer circulating tumor cells immunotherapy response to treatment head and neck cancer HPV EBV p16 Molecular imaging miRNA expression radiogenomics radiomic diagnosis biomarker glioblastoma radiation therapy MRI diffusion tensor imaging Hodgkin lymphoma diffuse large B-cell lymphoma staging response assessment locally advanced cervical cancer concurrent chemoradiotherapy treatment response follow up cystic tumor International Consensus Guidelines intraductal papillary mucinous neoplasms pancreatic neoplasms PD-1 PD-L1 response to therapy NSCLC positron-emission tomography single-photon emission computed tomography immune checkpoint inhibitors gold nanoparticle heat shock protein 70 spectral-CT |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910557309503321 |
|
Fanti Stefano
|
||
| Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2021 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||